NCT04858724 The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
| NCT ID | NCT04858724 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | IgA Nephropathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2020-12-01 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2020-12-01 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research. 2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis. 3. Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation. 4. Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.
Eligibility Criteria
Inclusion Criteria: 1. No age limit, no gender limit; 2. Kidney biopsy confirmed primary IgA nephropathy; 3. Sign the informed consent form voluntarily Exclusion Criteria: 1. IgA nephropathy is secondary to systemic diseases such as systemic lupus erythematosus and allergic purpura; 2. IgAN is clinically diagnosed but not confirmed by pathology; 3. The patient refuses to participate; 4. Patients judged by other investigators to be unsuitable for inclusion in the study.
Contact & Investigator
Jingyuan Xie
PRINCIPAL INVESTIGATOR
Ruijin Hospital
Frequently Asked Questions
Who can join the NCT04858724 clinical trial?
This trial is open to participants of all sexes, studying IgA Nephropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04858724 currently recruiting?
Yes, NCT04858724 is actively recruiting participants. Contact the research team at nephroxie@163.com for enrollment information.
Where is the NCT04858724 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT04858724 clinical trial?
NCT04858724 is sponsored by Ruijin Hospital. The principal investigator is Jingyuan Xie at Ruijin Hospital. The trial plans to enroll 2,000 participants.